Proteomics International Laboratories Ltd.

As of June 30, 2025, Proteomics International Laboratories Ltd. carries a market capitalization of 53.14M, placing it among publicly traded companies globally. Its enterprise value stands at 42.18M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Proteomics International Laboratories Ltd.'s next confirmed earnings release is scheduled for February 25, 2027.

As of June 30, 2025, Proteomics International Laboratories Ltd. has 163.52M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 45.44, and the price-to-book ratio stands at 4.04.

These figures are as of June 30, 2025. The EV/Sales ratio of 43.92 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 42.18M versus a market cap of 53.14M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, Proteomics International Laboratories Ltd. maintains a current ratio of 9.39, meaning it holds 9.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2025, Proteomics International Laboratories Ltd. posted a negative return on equity (ROE) of -71.87, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -63.26, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Proteomics International Laboratories Ltd.'s stock has declined approximately 67.14% over the past 52 weeks. The 50-day moving average sits at 0.14, while the 200-day moving average is 0.24.

Over the twelve months ended June 30, 2025, Proteomics International Laboratories Ltd. generated 960,389.00 in revenue and converted that into -8.11M in net income, yielding earnings per share of -0.06. EBITDA reached -10.00M, while operating income came in at -10.62M.

As of June 30, 2025, Proteomics International Laboratories Ltd. holds 11.04M in cash and equivalents against 277,739.00 in total debt, resulting in a net debt position of -11.04M. Total book value stands at 13.17M, with working capital of 12.08M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

These figures cover the twelve months ended June 30, 2025. The operating margin of -1,105.67 and net profit margin of -844.95 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -20.76, meaning Proteomics International Laboratories Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2025, Proteomics International Laboratories Ltd. has an Altman Z-Score of 12.67, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.